Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Arcturus Therapeutics Holdings Q3 2026 Results: Net Loss of $7.41M, Loss Narrows

Arcturus Therapeutics reported a decrease in total assets from $271.1 million at the end of 2025 to $215.3 million as of September 30, 2026, primarily driven by a reduction in cash and cash equivalents. The company's forward-looking statements highlight the termination of the CSL Collaboration Agreement and plans to advance its therapeutics pipeline, including ARCT-810 and ARCT-032, independently or with other partners.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue18.317.2
Profit before tax-7.4-13.4
Net income-7.4-13.4
EPS (diluted, $ a share)$-0.26$-0.49

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+6.7%
Operating margin-50.2%
Source

10-Q filed with the SEC, NASDAQ: ARCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Arcturus Therapeutics Holdings Inc.: key numbers

Share price
$8.31Close, Nov 16
Market cap
$240M
Shares outstanding
28.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Arcturus Therapeutics Holdings Inc.

All →
8:32 AM ET 8-K
Capital Raise

Arcturus Therapeutics Holdings Capital Raise of $50M

Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.

Value
$50M
Counterparty
Meiji Seika Pharma Co., Ltd.

“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”

Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
4:07 PM ET 8-K
Financial Results

Arcturus Therapeutics Holdings Financial Results

Arcturus Therapeutics reported Q3 2026 financial results, ending the period with $281.3 million in cash and equivalents. The company highlighted pipeline progress, including the completion of the myNEO acquisition and plans to complete enrollment for its ARCT-032 Phase 2 cystic fibrosis study by year-end 2026.

Term
Q3 2026

“The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-generation mRNA delivery platform, which demonstrated a 38-fold improvement over the key lipid in ARCT-810 in non-human primates.”

Joseph Payne, President & CEO of Arcturus
4:12 PM ET 8-K
Clinical Trial Data

Arcturus Therapeutics Holdings Clinical Trial Data

Arcturus Therapeutics released Phase 2 clinical data for ARCT-810, its mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency. The company also provided a strategic update on its broader mRNA delivery platform and technology pipeline.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.